EX-32.1 7 pstv-ex321_7.htm EX-32.1

EXHIBIT 32.1

CERTIFICATIONS PURSUANT TO 18 U.S.C. SECTION 1350/ SECURITIES EXCHANGE ACT RULE 13a-14(b), AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES – OXLEY ACT OF 2002

In connection with the Annual Report on Form 10-K of Plus Therapeutics, Inc. for the year ended December 31, 2021 as filed with the Securities and Exchange Commission on February 24, 2022, (the “Report”), Marc H. Hedrick, as President & Chief Executive Officer of Plus Therapeutics, Inc., and Andrew Sims, as Chief Financial Officer of Plus Therapeutics, Inc., each hereby certifies, respectively, that:

1. | The Report fully complies with the requirements of Section 13(a) of the Securities Exchange Act of 1934.

2. | The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of Plus Therapeutics, Inc.

|  | By: |  | /s/ Marc H. Hedrick, MD
Dated: February 24, 2022 |  |  |  | Marc H. Hedrick, MD
|  |  |  | President & Chief Executive Officer
|  | By: |  | /s/ Andrew Sims
Dated: February 24, 2022 |  |  |  | Andrew Sims
|  |  |  | Chief Financial Officer